FDA Approves Ganciclovir Ophthalmic Gel for Herpetic Keratitis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Ganciclovir Ophthalmic Gel for Herpetic Keratitis

NEW YORK -- September 16, 2009 -- The US Food and Drug Administration (FDA) has approved ganciclovir ophthalmic gel (Zirgan) 0.15% for the treatment of herpetic keratitis. The FDA granted orphan drug designation for this indication in April 2007.

The FDA approval was based on the results of 4 clinical trials comparing the efficacy and tolerability of ganciclovir ophthalmic gel with acyclovir ophthalmic ointment 3% in patients with herpetic keratitis.

In 1 open label, randomised, controlled, multicentre trial which enrolled 164 patients with herpetic keratitis, ganciclovir ophthalmic gel was non-inferior to acyclovir in patients with dendritic ulcers. Clinical resolution (defined as percentage of healed ulcers) at day 7 was achieved in 77% of patients treated with ganciclovir ophthalmic gel versus 72% of patients treated with acyclovir.

In 3 randomised, single-masked, controlled multicentre trials which enrolled 213 patients, ganciclovir ophthalmic gel was non-inferior to acyclovir. Clinical resolution at day 7 was achieved in 72% of patients treated with ganciclovir ophthalmic gel versus 69% of patients treated with acyclovir.

SOURCE: Sirion Therapeutics, Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities